Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon
The responses and tolerance can be further enhanced with a combination of thalidomide and corticosteroids initially for a short period. 3 IFNα targets the malignant clone in PV/myeloproliferative neoplasm to achieve complete haematological and molecular response. 4 It is also effective in fibrosis...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pathology 2012-08, Vol.65 (8), p.762-763 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 763 |
|---|---|
| container_issue | 8 |
| container_start_page | 762 |
| container_title | Journal of clinical pathology |
| container_volume | 65 |
| creator | Hebballi, Sangam Akiki, Susanna Bareford, David |
| description | The responses and tolerance can be further enhanced with a combination of thalidomide and corticosteroids initially for a short period. 3 IFNα targets the malignant clone in PV/myeloproliferative neoplasm to achieve complete haematological and molecular response. 4 It is also effective in fibrosis secondary to PV with residual haematopoietic function 5 6 by its broad physiological effects on haematopoiesis/megakaryopoiesis. 7 JAK2V617F mutation, a screening tool in PV and ET, can be quantified and used as a tool to monitor minimal residual disease and assess treatment efficacy. 7 Detection and quantitation of the JAK2V617F allele in genomic DNA was determined by real-time quantitative PCR (AB 7900, Life Technologies Corp., Carlsbad, California) analysis using a commercially validated CE (Conformité Européene) marked kit 8 (JAK2 MutaQuant; Ipsogen SA, Marseille cedex 9, France). |
| doi_str_mv | 10.1136/jclinpath-2011-200598 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1781040116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4022601201</sourcerecordid><originalsourceid>FETCH-LOGICAL-b331t-c0d8334a08cc12f2a43af9dbca9f9b637ec1ce286227893c5164e265ed493dde3</originalsourceid><addsrcrecordid>eNqNkMFq3DAQhkVoyG43fYQEQ89uNZIs28dgmrR0aSAkDfQiZElmtbEtV9KS7NtXi7N77mXmMN8_I30IXQH-AkD5163q7TjJuMkJBkgFF3V1hpbASpIzYPwDWmJMIK9LxhfoYwhbjIGWQC_QghAGBBd0icSDCa7fRevGzHXZ5ELMJ9fv1T5upBmsyoa96V1nW--CDdmrjZtMZsoNrR3lMZbY3mo3WG0yOerMjtH4zng3XqLzTvbBfHrvK_R0--2x-Z6v7-9-NDfrvKUUYq6wrihlEldKAemIZFR2tW6VrLu65bQ0CpQhFSekrGqqCuDMEF4YzWqqtaEr9HneO3n3d2dCFFu382M6KaCsALMkiSeqmCmVfhO86cTk7SD9XgAWB63ipFUctIpZa8pdv2_ftYPRp9TRYwLyGbAhmrfTXPoXwUtaFuLX70b8-QnV-rmpRZN4PPPtsP3PN_wDWh6WYg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781040116</pqid></control><display><type>article</type><title>Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Hebballi, Sangam ; Akiki, Susanna ; Bareford, David</creator><creatorcontrib>Hebballi, Sangam ; Akiki, Susanna ; Bareford, David</creatorcontrib><description>The responses and tolerance can be further enhanced with a combination of thalidomide and corticosteroids initially for a short period. 3 IFNα targets the malignant clone in PV/myeloproliferative neoplasm to achieve complete haematological and molecular response. 4 It is also effective in fibrosis secondary to PV with residual haematopoietic function 5 6 by its broad physiological effects on haematopoiesis/megakaryopoiesis. 7 JAK2V617F mutation, a screening tool in PV and ET, can be quantified and used as a tool to monitor minimal residual disease and assess treatment efficacy. 7 Detection and quantitation of the JAK2V617F allele in genomic DNA was determined by real-time quantitative PCR (AB 7900, Life Technologies Corp., Carlsbad, California) analysis using a commercially validated CE (Conformité Européene) marked kit 8 (JAK2 MutaQuant; Ipsogen SA, Marseille cedex 9, France).</description><identifier>ISSN: 0021-9746</identifier><identifier>EISSN: 1472-4146</identifier><identifier>DOI: 10.1136/jclinpath-2011-200598</identifier><identifier>PMID: 22412053</identifier><identifier>CODEN: JCPAAK</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and Association of Clinical Pathologists</publisher><subject>Angiogenesis ; Bone marrow ; Bone Marrow Examination ; DNA Mutational Analysis ; Drug Therapy, Combination ; Female ; Haemato-oncology ; haematology ; haemoglobinopathy ; Hematology ; Histology ; Humans ; Immunologic Factors - therapeutic use ; Interferon-alpha - therapeutic use ; Janus Kinase 2 - genetics ; Middle Aged ; Mortality ; Mutation ; myeloproliferative disease ; platelets ; Polycythemia Vera - complications ; Polycythemia Vera - diagnosis ; Polycythemia Vera - drug therapy ; Polycythemia Vera - genetics ; Polyethylene Glycols - therapeutic use ; Primary Myelofibrosis - diagnosis ; Primary Myelofibrosis - drug therapy ; Primary Myelofibrosis - etiology ; Recombinant Proteins - therapeutic use ; sickle cell disease ; Stem cells ; Thalidomide - therapeutic use ; Time Factors ; Transplants & implants ; Treatment Outcome ; Tumors</subject><ispartof>Journal of clinical pathology, 2012-08, Vol.65 (8), p.762-763</ispartof><rights>2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2012 (c) 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-b331t-c0d8334a08cc12f2a43af9dbca9f9b637ec1ce286227893c5164e265ed493dde3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jcp.bmj.com/content/65/8/762.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://jcp.bmj.com/content/65/8/762.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,315,781,785,3197,23573,27926,27927,77602,77633</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22412053$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hebballi, Sangam</creatorcontrib><creatorcontrib>Akiki, Susanna</creatorcontrib><creatorcontrib>Bareford, David</creatorcontrib><title>Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon</title><title>Journal of clinical pathology</title><addtitle>J Clin Pathol</addtitle><description>The responses and tolerance can be further enhanced with a combination of thalidomide and corticosteroids initially for a short period. 3 IFNα targets the malignant clone in PV/myeloproliferative neoplasm to achieve complete haematological and molecular response. 4 It is also effective in fibrosis secondary to PV with residual haematopoietic function 5 6 by its broad physiological effects on haematopoiesis/megakaryopoiesis. 7 JAK2V617F mutation, a screening tool in PV and ET, can be quantified and used as a tool to monitor minimal residual disease and assess treatment efficacy. 7 Detection and quantitation of the JAK2V617F allele in genomic DNA was determined by real-time quantitative PCR (AB 7900, Life Technologies Corp., Carlsbad, California) analysis using a commercially validated CE (Conformité Européene) marked kit 8 (JAK2 MutaQuant; Ipsogen SA, Marseille cedex 9, France).</description><subject>Angiogenesis</subject><subject>Bone marrow</subject><subject>Bone Marrow Examination</subject><subject>DNA Mutational Analysis</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Haemato-oncology</subject><subject>haematology</subject><subject>haemoglobinopathy</subject><subject>Hematology</subject><subject>Histology</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Janus Kinase 2 - genetics</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Mutation</subject><subject>myeloproliferative disease</subject><subject>platelets</subject><subject>Polycythemia Vera - complications</subject><subject>Polycythemia Vera - diagnosis</subject><subject>Polycythemia Vera - drug therapy</subject><subject>Polycythemia Vera - genetics</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Primary Myelofibrosis - diagnosis</subject><subject>Primary Myelofibrosis - drug therapy</subject><subject>Primary Myelofibrosis - etiology</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>sickle cell disease</subject><subject>Stem cells</subject><subject>Thalidomide - therapeutic use</subject><subject>Time Factors</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0021-9746</issn><issn>1472-4146</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkMFq3DAQhkVoyG43fYQEQ89uNZIs28dgmrR0aSAkDfQiZElmtbEtV9KS7NtXi7N77mXmMN8_I30IXQH-AkD5163q7TjJuMkJBkgFF3V1hpbASpIzYPwDWmJMIK9LxhfoYwhbjIGWQC_QghAGBBd0icSDCa7fRevGzHXZ5ELMJ9fv1T5upBmsyoa96V1nW--CDdmrjZtMZsoNrR3lMZbY3mo3WG0yOerMjtH4zng3XqLzTvbBfHrvK_R0--2x-Z6v7-9-NDfrvKUUYq6wrihlEldKAemIZFR2tW6VrLu65bQ0CpQhFSekrGqqCuDMEF4YzWqqtaEr9HneO3n3d2dCFFu382M6KaCsALMkiSeqmCmVfhO86cTk7SD9XgAWB63ipFUctIpZa8pdv2_ftYPRp9TRYwLyGbAhmrfTXPoXwUtaFuLX70b8-QnV-rmpRZN4PPPtsP3PN_wDWh6WYg</recordid><startdate>201208</startdate><enddate>201208</enddate><creator>Hebballi, Sangam</creator><creator>Akiki, Susanna</creator><creator>Bareford, David</creator><general>BMJ Publishing Group Ltd and Association of Clinical Pathologists</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201208</creationdate><title>Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon</title><author>Hebballi, Sangam ; Akiki, Susanna ; Bareford, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b331t-c0d8334a08cc12f2a43af9dbca9f9b637ec1ce286227893c5164e265ed493dde3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Angiogenesis</topic><topic>Bone marrow</topic><topic>Bone Marrow Examination</topic><topic>DNA Mutational Analysis</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Haemato-oncology</topic><topic>haematology</topic><topic>haemoglobinopathy</topic><topic>Hematology</topic><topic>Histology</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Janus Kinase 2 - genetics</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Mutation</topic><topic>myeloproliferative disease</topic><topic>platelets</topic><topic>Polycythemia Vera - complications</topic><topic>Polycythemia Vera - diagnosis</topic><topic>Polycythemia Vera - drug therapy</topic><topic>Polycythemia Vera - genetics</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Primary Myelofibrosis - diagnosis</topic><topic>Primary Myelofibrosis - drug therapy</topic><topic>Primary Myelofibrosis - etiology</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>sickle cell disease</topic><topic>Stem cells</topic><topic>Thalidomide - therapeutic use</topic><topic>Time Factors</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hebballi, Sangam</creatorcontrib><creatorcontrib>Akiki, Susanna</creatorcontrib><creatorcontrib>Bareford, David</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hebballi, Sangam</au><au>Akiki, Susanna</au><au>Bareford, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon</atitle><jtitle>Journal of clinical pathology</jtitle><addtitle>J Clin Pathol</addtitle><date>2012-08</date><risdate>2012</risdate><volume>65</volume><issue>8</issue><spage>762</spage><epage>763</epage><pages>762-763</pages><issn>0021-9746</issn><eissn>1472-4146</eissn><coden>JCPAAK</coden><abstract>The responses and tolerance can be further enhanced with a combination of thalidomide and corticosteroids initially for a short period. 3 IFNα targets the malignant clone in PV/myeloproliferative neoplasm to achieve complete haematological and molecular response. 4 It is also effective in fibrosis secondary to PV with residual haematopoietic function 5 6 by its broad physiological effects on haematopoiesis/megakaryopoiesis. 7 JAK2V617F mutation, a screening tool in PV and ET, can be quantified and used as a tool to monitor minimal residual disease and assess treatment efficacy. 7 Detection and quantitation of the JAK2V617F allele in genomic DNA was determined by real-time quantitative PCR (AB 7900, Life Technologies Corp., Carlsbad, California) analysis using a commercially validated CE (Conformité Européene) marked kit 8 (JAK2 MutaQuant; Ipsogen SA, Marseille cedex 9, France).</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and Association of Clinical Pathologists</pub><pmid>22412053</pmid><doi>10.1136/jclinpath-2011-200598</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9746 |
| ispartof | Journal of clinical pathology, 2012-08, Vol.65 (8), p.762-763 |
| issn | 0021-9746 1472-4146 |
| language | eng |
| recordid | cdi_proquest_journals_1781040116 |
| source | MEDLINE; BMJ Journals - NESLi2; PubMed Central |
| subjects | Angiogenesis Bone marrow Bone Marrow Examination DNA Mutational Analysis Drug Therapy, Combination Female Haemato-oncology haematology haemoglobinopathy Hematology Histology Humans Immunologic Factors - therapeutic use Interferon-alpha - therapeutic use Janus Kinase 2 - genetics Middle Aged Mortality Mutation myeloproliferative disease platelets Polycythemia Vera - complications Polycythemia Vera - diagnosis Polycythemia Vera - drug therapy Polycythemia Vera - genetics Polyethylene Glycols - therapeutic use Primary Myelofibrosis - diagnosis Primary Myelofibrosis - drug therapy Primary Myelofibrosis - etiology Recombinant Proteins - therapeutic use sickle cell disease Stem cells Thalidomide - therapeutic use Time Factors Transplants & implants Treatment Outcome Tumors |
| title | Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T06%3A49%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Resolution%20of%20post-polycythaemic%20myelofibrosis%20with%20a%20combination%20of%20thalidomide%20and%20interferon&rft.jtitle=Journal%20of%20clinical%20pathology&rft.au=Hebballi,%20Sangam&rft.date=2012-08&rft.volume=65&rft.issue=8&rft.spage=762&rft.epage=763&rft.pages=762-763&rft.issn=0021-9746&rft.eissn=1472-4146&rft.coden=JCPAAK&rft_id=info:doi/10.1136/jclinpath-2011-200598&rft_dat=%3Cproquest_cross%3E4022601201%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781040116&rft_id=info:pmid/22412053&rfr_iscdi=true |